Pain

Filtering The Facts: The Urology Care Foundation Spreads Awareness for National Kidney Month

Retrieved on: 
Friday, March 1, 2024

BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.

Key Points: 
  • BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.
  • The kidneys also make hormones that help to keep blood pressure stable, make red blood cells and help keep bones strong.
  • Kidney health deserves equal awareness,” said Dr. Timothy Averch, chair of the Urology Care Foundation’s Kidney and Adrenal Health Committee.
  • For National Kidney Month, the Urology Care Foundation is focusing on information about kidney cancer and kidney stones:
    It is estimated that there will be over 81,000 new kidney cancer cases and over 14,000 cancer deaths in the United States in 2024.

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024

VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • We also continue to evaluate other neurological indications that present a potential fit for XEN1101’s novel mechanism and product profile.
  • Other income was $8.7 million for the fourth quarter of 2023, and $31.4 million for the year ended 2023, compared to $7.1 million and $3.9 million for the same periods in 2022.
  • Net loss was $44.7 million for the fourth quarter of 2023, and $182.4 million for the year ended 2023, compared to $37.4 million and $125.4 million for the same periods in 2022, respectively.
  • Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its fourth quarter and full year 2023 results.

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Retrieved on: 
Thursday, February 29, 2024

THE WOODLANDS, TX, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has entered into a clinical site agreement with “АКFА MEDLINE" Ltd., for its PoC human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • Additionally, Autonomix announced the selection of Clinical Accelerator and Qmed, full service Clinical Research Organizations (CROs) specializing in medical devices to support the PoC human clinical trial.
  • Clinical Accelerator will be responsible for managing the clinical operations in country, including recruiting patients, SIV work, and patient treatment records and Qmed will be responsible for managing protocol and trial reporting, as well as managing patient data.
  • Lori Bisson, Chief Executive Officer of Autonomix commented, “We are pleased to execute these important agreements and final steps towards commencing patient enrollment in our first PoC human clinical trial.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023.

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023.
  • Reduction in net cash usage for operating activities:
    For the three months ended December 31, 2023, net cash usage was US$12.3 million, a 25% reduction versus the comparative quarter in FY2023.
  • For the six months ended December 31, 2023, net cash usage was US$26.6 million, a 14% reduction versus the comparative period in FY2023.
  • Manufacturing reduced by 47% for the six months ended December 31, 2023, from US$12.8 million to US$6.7 million.

Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions

Retrieved on: 
Tuesday, February 27, 2024

Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, are pleased to announce Chromocell’s first Development and License Agreement (“Agreement”).

Key Points: 
  • Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, are pleased to announce Chromocell’s first Development and License Agreement (“Agreement”).
  • This strategic alliance underscores both Benuvia and Chromocell’s commitment to advancing healthcare through innovative research, development, and commercialization efforts.
  • "We are excited to partner with Chromocell, a company that shares our passion for innovation and our commitment to improving patient outcomes," said Darwin Richardson, CEO of Benuvia Operations LLC.
  • "This partnership will leverage our combined expertise to accelerate the development of potentially groundbreaking therapies, aimed at marking a new era in healthcare solutions."

Six Years Strong: Founder of Revitalist Kathryn Walker’s Continuous Leadership in Revolutionizing Mental Health Care

Retrieved on: 
Friday, February 23, 2024

The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.

Key Points: 
  • The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.
  • Kate NeuroPsych represents a groundbreaking approach to mental health care — offering 24/7 availability, personalized recommendations, and worldwide access — being designed by scientific leaders who are positively disrupting healthcare delivery at Revitalist and Sama Therapeutics .
  • Looking ahead, Kathryn envisions a future where psychedelics are normalized as essential tools in mental health care.
  • With each milestone she achieves, Kathryn Walker continues to redefine the boundaries of mental health care and inspire hope for a brighter, more compassionate future.

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

Retrieved on: 
Friday, February 23, 2024

If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).

Key Points: 
  • If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).
  • “The CHMP’s positive opinion reinforces the impact QALSODY can have in SOD1-ALS and further demonstrates Biogen’s commitment to address the unmet needs of people living with ALS and neuromuscular diseases,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen.
  • Trends towards improvement in the physical abilities of participants who received QALSODY were seen compared to those who received placebo, as measured by the ALS Functional Ratings Scale-Revised (ALSFRS-R).
  • Serious neurologic events, including myelitis and/or radiculitis; papilledema and elevated intracranial pressure; and aseptic meningitis have also been reported.

BioElectronics Corporation Announces the Publication of Pilot Study Results

Retrieved on: 
Friday, February 23, 2024

FREDERICK, MD, Feb. 23, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device.

Key Points: 
  • FREDERICK, MD, Feb. 23, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation ( https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device.
  • "Treating intractable postamputation pain with wearable, non-invasive, non-thermal, pulsed shortwave (radiofrequency) therapy: a randomized, double-masked, sham-controlled, crossover pilot study" is now published at: https://rapm.bmj.com/content/early/2024/02/21/rapm-2023-105154 The study was investigator sponsored and funded by the University of California San Diego Department of Anesthesiology.
  • The study design had patients first wear BioElectronics’ Model 088 device (about ½ wore the sham device and the remaining wore the active device) on the residual part of the limb for 28 days.
  • Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device to address this significant unmet medical need.

Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study

Retrieved on: 
Thursday, February 22, 2024

THE WOODLANDS, TX, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has completed selection of Principal Investigators for its proof-of-concept human clinical study evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain. Additionally, the Principal Investigators have successfully completed training for the PoC study.

Key Points: 
  • Additionally, the Principal Investigators have successfully completed training for the PoC study.
  • “We are building important momentum with the advancement of our PoC human clinical study.
  • We worked diligently to identify and secure our Principal Investigators for the study and have completed the training for this first study ever to evaluate RF ablation in a transvascular approach.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the study.

Calian Wins Contract to Support Clinical Trial for ZYUS Life Sciences’ Lead Drug Product Candidate

Retrieved on: 
Tuesday, February 20, 2024

Calian's full-service Contract Research Organization (CRO) will apply its extensive clinical trial management experience to support a Phase 2 Clinical Trial for Trichomylin softgel capsules.

Key Points: 
  • Calian's full-service Contract Research Organization (CRO) will apply its extensive clinical trial management experience to support a Phase 2 Clinical Trial for Trichomylin softgel capsules.
  • “Calian will apply our industry-leading expertise to support this Phase 2 Clinical Trial and further ZYUS’ pursuit of transformational impact on patients’ lives,” says Derek Clark, President, Calian Health.
  • Calian will provide full-service, end-to-end expertise to support this trial, including medical writing, regulatory affairs, clinical operations, site monitoring, data management, medical monitoring and quality assurance.
  • By collaborating with an industry leading contract research organization with extensive experience in clinical trial management, we can leverage invaluable knowledge and expertise."